IDEXX Laboratories, Inc. $IDXX Stock Purchased by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 233.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,801 shares of the company’s stock after purchasing an additional 1,261 shares during the quarter. Edmond DE Rothschild Holding S.A.’s holdings in IDEXX Laboratories were worth $940,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of IDXX. J.Safra Asset Management Corp bought a new position in IDEXX Laboratories in the second quarter valued at about $25,000. Elevation Wealth Partners LLC increased its stake in shares of IDEXX Laboratories by 188.2% in the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after buying an additional 32 shares during the period. Meeder Asset Management Inc. raised its holdings in IDEXX Laboratories by 189.5% in the 3rd quarter. Meeder Asset Management Inc. now owns 55 shares of the company’s stock valued at $29,000 after buying an additional 36 shares during the last quarter. Pension & Wealth Management Advisors Inc. acquired a new stake in IDEXX Laboratories during the 3rd quarter worth approximately $29,000. Finally, Arlington Trust Co LLC boosted its position in IDEXX Laboratories by 46.3% during the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock worth $32,000 after buying an additional 19 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In related news, EVP Sharon Underberg sold 8,906 shares of the firm’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $688.59, for a total transaction of $6,132,582.54. Following the completion of the sale, the executive vice president owned 7,169 shares in the company, valued at approximately $4,936,501.71. This trade represents a 55.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Daniel Junius sold 1,200 shares of the business’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $704.07, for a total value of $844,884.00. Following the completion of the sale, the director owned 2,361 shares in the company, valued at approximately $1,662,309.27. The trade was a 33.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 41,428 shares of company stock worth $28,567,934. Company insiders own 0.79% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $676.21 on Friday. The firm’s 50-day moving average price is $579.87 and its 200-day moving average price is $574.26. IDEXX Laboratories, Inc. has a 1-year low of $500.61 and a 1-year high of $769.98. The company has a current ratio of 1.19, a quick ratio of 0.88 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $53.28 billion, a P/E ratio of 45.60 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported $3.96 EPS for the quarter, topping the consensus estimate of $3.71 by $0.25. IDEXX Laboratories had a net margin of 25.36% and a return on equity of 71.04%. The company had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.19 billion. During the same period in the previous year, the firm posted $3.22 earnings per share. The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 15.05 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on IDXX shares. Citigroup upped their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Barclays cut their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. KeyCorp initiated coverage on shares of IDEXX Laboratories in a research note on Monday, October 12th. They issued a “sector weight” rating on the stock. JPMorgan Chase & Co. decreased their price objective on IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a report on Friday, October 16th. Finally, The Goldman Sachs Group initiated coverage on IDEXX Laboratories in a research note on Friday, October 16th. They issued a “buy” rating and a $740.00 price target for the company. Seven research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $717.27.

Check Out Our Latest Stock Report on IDXX

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.

Recommended Stories

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.